O
Outlook Therapeutics Inc.
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of Outlook Therapeutics Inc.
Revenue—FY 2023
Operating income−$53.1M▲ 15.8% YoY
Net profit−$59.0M▲ 10.7% YoY
Shareholders' equity−$24.3M
Market cap$120MOTLK · $0.49
Competitors10identified
About Outlook Therapeutics Inc.
Sectors
Company details
- Founded
- 2016
- Listed
- Nasdaq: OTLK (since 2016)
Operational Areas of Outlook Therapeutics Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameOutlook Therapeutics Inc.
TickerOTLK
ExchangeNasdaq
CountryUnited States
SEC CIK0001649989
Listed since2016
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
OTLK · Nasdaq · SEC CIK 0001649989
Last price · 30 Oct 2026
$0.49
−9.43%
Market cap$120M
P/E—On FY 2023 diluted EPS
Volume7,059,563
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOUnited StatesListed 2016
OTLK share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Outlook Therapeutics Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.